A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. [electronic resource]
Producer: 20150120Description: 577-82 p. digitalISSN:- 1556-1380
- Adenocarcinoma -- drug therapy
- Adenocarcinoma, Bronchiolo-Alveolar -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor -- urine
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Carcinoma, Squamous Cell -- drug therapy
- Cyclooxygenase 2 Inhibitors -- therapeutic use
- Disease Progression
- Double-Blind Method
- Erlotinib Hydrochloride
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Prognosis
- Prospective Studies
- Prostaglandins -- urine
- Protein Kinase Inhibitors -- therapeutic use
- Pyrroles -- therapeutic use
- Quinazolines -- therapeutic use
- Sulfonamides -- therapeutic use
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.